Public Health Emergency - Leading a Nation Prepared
Date: September 28, 2011
Company: RxBio Inc. of Johnson City, Tenn.
Contract amount: $15 million over two years
About this contract: RxBio Inc will study the efficacy of its drug Rx100, which may protect against radiation-induced gastrointestinal injury by interrupting programmed cell death, known as apoptosis. Preliminary data suggests that Rx100 can protect or mitigate injury and improve survival if administered up to 72 hours after deadly whole-body radiation exposure. The contract also supports development of manufacturing processes for the drug.
Additional information: BARDA is seeking additional proposals for products that potentially could treat or prevent illness and injury from acute radiation syndrome, as well as improved diagnostic tools to measure the radiation dose a person has absorbed after a nuclear denotation or radiation accident. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at www.fbo.gov.
Press Release: BARDA funds development of five drugs to protect against radiation
Procurement Announcement: Contract Awarded under BAA-BARDA-09-34
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages